Cargando…

Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines

Considering the clinical significance for myocarditis and pericarditis after immunization with mRNA COVID-19 vaccines, the present pharmacovigilance study aimed to describe these events reported with mRNA COVID-19 vaccines in the Vaccine Adverse Events Reporting System (VAERS). From 1990 to July 202...

Descripción completa

Detalles Bibliográficos
Autores principales: Rafaniello, Concetta, Gaio, Mario, Zinzi, Alessia, Sullo, Maria Giuseppa, Liguori, Valerio, Ferraro, Marialuisa, Petronzelli, Fiorella, Felicetti, Patrizia, Marchione, Pasquale, Marra, Anna Rosa, Rossi, Francesco, De Angelis, Antonella, Capuano, Annalisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145505/
https://www.ncbi.nlm.nih.gov/pubmed/35631352
http://dx.doi.org/10.3390/ph15050525
_version_ 1784716331863506944
author Rafaniello, Concetta
Gaio, Mario
Zinzi, Alessia
Sullo, Maria Giuseppa
Liguori, Valerio
Ferraro, Marialuisa
Petronzelli, Fiorella
Felicetti, Patrizia
Marchione, Pasquale
Marra, Anna Rosa
Rossi, Francesco
De Angelis, Antonella
Capuano, Annalisa
author_facet Rafaniello, Concetta
Gaio, Mario
Zinzi, Alessia
Sullo, Maria Giuseppa
Liguori, Valerio
Ferraro, Marialuisa
Petronzelli, Fiorella
Felicetti, Patrizia
Marchione, Pasquale
Marra, Anna Rosa
Rossi, Francesco
De Angelis, Antonella
Capuano, Annalisa
author_sort Rafaniello, Concetta
collection PubMed
description Considering the clinical significance for myocarditis and pericarditis after immunization with mRNA COVID-19 vaccines, the present pharmacovigilance study aimed to describe these events reported with mRNA COVID-19 vaccines in the Vaccine Adverse Events Reporting System (VAERS). From 1990 to July 2021, the mRNA vaccines were the most common suspected vaccines related to suspected cases of myocarditis and/or pericarditis (myocarditis: N = 1,165; 64.0%; pericarditis: N = 743; 55.1%), followed by smallpox vaccines (myocarditis: N = 222; 12.2%; pericarditis: N = 200; 14.8%). We assessed all suspected cases through the case definition and classification of the Brighton Collaboration Group, and only definitive, probable, and possible cases were included in the analysis. Our findings suggested that myocarditis and pericarditis mostly involve young male, especially after the second dose with a brief time to onset. Nevertheless, this risk is lower (0.38/100,000 vaccinated people; 95% CI 0.36–0.40) than the risk of developing myocarditis after SARS-CoV-2 infection (1000–4000 per 100,000 people) and the risk of developing “common” viral myocarditis (1–10 per 100,000 people/year). Comparing with the smallpox vaccine, for which is already well known the association with myocarditis and pericarditis, our analysis showed a lower probability of reporting myocarditis (ROR 0.12, 95% CI 0.10–0.14) and pericarditis (ROR 0.06, 95% CI 0.05–0.08) following immunization with mRNA COVID-19 vaccines.
format Online
Article
Text
id pubmed-9145505
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91455052022-05-29 Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines Rafaniello, Concetta Gaio, Mario Zinzi, Alessia Sullo, Maria Giuseppa Liguori, Valerio Ferraro, Marialuisa Petronzelli, Fiorella Felicetti, Patrizia Marchione, Pasquale Marra, Anna Rosa Rossi, Francesco De Angelis, Antonella Capuano, Annalisa Pharmaceuticals (Basel) Article Considering the clinical significance for myocarditis and pericarditis after immunization with mRNA COVID-19 vaccines, the present pharmacovigilance study aimed to describe these events reported with mRNA COVID-19 vaccines in the Vaccine Adverse Events Reporting System (VAERS). From 1990 to July 2021, the mRNA vaccines were the most common suspected vaccines related to suspected cases of myocarditis and/or pericarditis (myocarditis: N = 1,165; 64.0%; pericarditis: N = 743; 55.1%), followed by smallpox vaccines (myocarditis: N = 222; 12.2%; pericarditis: N = 200; 14.8%). We assessed all suspected cases through the case definition and classification of the Brighton Collaboration Group, and only definitive, probable, and possible cases were included in the analysis. Our findings suggested that myocarditis and pericarditis mostly involve young male, especially after the second dose with a brief time to onset. Nevertheless, this risk is lower (0.38/100,000 vaccinated people; 95% CI 0.36–0.40) than the risk of developing myocarditis after SARS-CoV-2 infection (1000–4000 per 100,000 people) and the risk of developing “common” viral myocarditis (1–10 per 100,000 people/year). Comparing with the smallpox vaccine, for which is already well known the association with myocarditis and pericarditis, our analysis showed a lower probability of reporting myocarditis (ROR 0.12, 95% CI 0.10–0.14) and pericarditis (ROR 0.06, 95% CI 0.05–0.08) following immunization with mRNA COVID-19 vaccines. MDPI 2022-04-25 /pmc/articles/PMC9145505/ /pubmed/35631352 http://dx.doi.org/10.3390/ph15050525 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rafaniello, Concetta
Gaio, Mario
Zinzi, Alessia
Sullo, Maria Giuseppa
Liguori, Valerio
Ferraro, Marialuisa
Petronzelli, Fiorella
Felicetti, Patrizia
Marchione, Pasquale
Marra, Anna Rosa
Rossi, Francesco
De Angelis, Antonella
Capuano, Annalisa
Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines
title Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines
title_full Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines
title_fullStr Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines
title_full_unstemmed Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines
title_short Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines
title_sort disentangling a thorny issue: myocarditis and pericarditis post covid-19 and following mrna covid-19 vaccines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145505/
https://www.ncbi.nlm.nih.gov/pubmed/35631352
http://dx.doi.org/10.3390/ph15050525
work_keys_str_mv AT rafanielloconcetta disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines
AT gaiomario disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines
AT zinzialessia disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines
AT sullomariagiuseppa disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines
AT liguorivalerio disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines
AT ferraromarialuisa disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines
AT petronzellifiorella disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines
AT felicettipatrizia disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines
AT marchionepasquale disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines
AT marraannarosa disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines
AT rossifrancesco disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines
AT deangelisantonella disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines
AT capuanoannalisa disentanglingathornyissuemyocarditisandpericarditispostcovid19andfollowingmrnacovid19vaccines